Abstract 149P
Background
HER2 blockade in ERBB2+ BC can boost the immune system and inhibit cell proliferation and survival. Here, we aimed to identify early molecular changes following a single dose of HP and its association with subsequent pCR following neoadjuvant HP-based chemotherapy.
Methods
Patients (pts) with stage I-III ERBB2+BC were treated with neoadjuvant pertuzumab+trastuzumab+paclitaxel (THP)x16w. Paired tumor biopsies were obtained at baseline (D1) and at day 8 (D8) following a loading-dose of HP, prior to weekly paclitaxel addition. HER2DX gene expression signatures and the expression of 185 genes were evaluated in both timepoints. Paired SAM analyses (FDR<5%) and t-tests determined significant changes between D1-D8. Logistic regression analyses identified associations with pCR (ypT0/isN0).
Results
Gene expression was evaluated in paired samples in 49 out of 52 pts (94%). cT1-2 disease represented 85% of cases, cN0 59%, and 67% were HR+. The overall pCR rate was 45.6% and 55.3% when ypT1miN0 was considered. In all pts, HP induced a significant decrease in HER2DX proliferation, HER2 amplicon, pCR, risk and ERBB2 scores, and in 81 (43.8%) genes including KRT18, SPDEF, MUCL1 or FOXA1; and a significant increase in the HER2DX IGG signature and 84 (45.4%) genes including GPNMB, CD68, CD86 or CD4. At D8, the HER2DX IGG signature (p=0.002) and 61 (33.0%) genes including LY9 (p<0.001), CD8A (p<0.001), CD27 (p<0.001) or GZMA (p<0.001) were significantly associated with pCR. At D1, pCR rates in HER2DX IGG-high, medium and low were 71.4%, 22.2% and 25.0%, respectively. At D8, pCR rates in HER2DX IGG-high, medium and low were 81.0%, 33.3% and 6.3%, respectively. The ratio between D8 and D1 of HER2DX pCR (p=0.006) and risk (p=0.026) scores and 38 (20.5%) genes including S100A9 (p=0.006), TRPV6 (p=0.008), GPNMB (p=0.013) or LY9 (p=0.016) were significantly associated with pCR.
Conclusions
In early-stage ERBB2+ BC, a single dose of HP induces significant biological changes that may better predict pCR. At day 8, pts with high expression of HER2DX immune signature and immune-related genes have a higher probability of achieving a pCR following THP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Reveal Genomics S.L.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01